CC
TVRD

Centiva Capital’s Tvardi Therapeutics TVRD Stock Holding History

Centiva Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,689
Closed -$25K – 2702
2024
Q2 		$25K Buy
+2,689
New +$64.1K ﹤0.01% 1961

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's TVRD Position: Q3 2024 in Review

Centiva Capital sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 2,689 shares — an estimated $25K sold.

Centiva Capital first reported a position in TVRD in Q2 2024 and held it in 1 quarter. The position peaked at $25K in Q2 2024. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • Centiva Capital reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 2,689 Tvardi Therapeutics shares in Q3 2024, an estimated $25K.
  • Centiva Capital first reported a position in Tvardi Therapeutics in Q2 2024 and held it in 1 quarter.
  • Centiva Capital's Tvardi Therapeutics position peaked at $25K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.